Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Temozolomide in Unfit Advanced Neuroendocrine Neoplasms
NCT05554003Phase 2Recruiting
- Sponsor
- European Institute of Oncology
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in neuroendocrine neoplasms (NENs), sponsored by European Institute of Oncology. Primary endpoint: Progression-Free Survival at 3 years. Started Jan 2022; status: recruiting.
02
Drugs
temozolomide
03
Conditions
neuroendocrine neoplasms (NENs)
Beyond the preview
Go deeper on NCT05554003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05554003.